A cost-effectiveness analysis of directly observed therapy vs self- administered therapy for treatment of tuberculosis

Chest

Volumn 112, Issue 1, 1997, Pages 63-70

  Burman, William J ^a,b,e   Dalton, Craig B ^c   Cohn, David L ^a,b   Butler, James R G ^d   Reves, Randall R ^a,b  

^a Denver Disease Control Service   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^e DENVER PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; Decision analysis; Directly observed therapy; Tuberculosis

Indexed keywords

ANALYTIC METHOD; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE TRANSMISSION; HEALTH CARE SYSTEM; HOSPITALIZATION; INFECTION CONTROL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PUBLIC HEALTH; RELAPSE; TUBERCULOSIS;

EID: 0030878854     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.112.1.63     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. Expanded tuberculosis surveillance and tuberculosis morbidity - United States, 1993. MMWR 1994; 43:361-66
2. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 1995; 273:220-26
3. Selwyn PA, Hartell D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545-50
4. Burwen DR, Bloch AB, Griffin LD, et al. National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome. Arch Intern Med 1995; 155:1281-86
5. Cantwell MF, Snider DE Jr, Cantlien GM, et al. Epidemiology of tuberculosis in the United States. 1985 through 1992. JAMA 1994; 272:535-39
6. McKenna MT, McCray E. Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med 1995; 332:1071-76
7. Torres RA, Mani S, Altholtz J, et al. Human immunodeficiency virus infection among homeless men in a New York City shelter: association with Mycobacterium tuberculosis infection. Arch Intern Med 1990; 150:2030-36
8. Brudney K, Dobkin J. Resurgent tuberculosis in New York City: human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144:745-49
9. Nolan CM, Elarth AM, Barr H, et al. An outbreak of tuberculosis in a shelter for homeless men: a description of its evolution and control. Am Rev Respir Dis 1991; 143:257-61
10. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: a population-based study using conventional and molecular methods. N Engl J Med 1994; 330:1703-09
11. Centers for Disease Control. Primary resistance to antituberculosis drugs - United States. MMWR 1983; 32:521-23
12. Bloch AB, Canthen GM. Onorato IM, et al. Nationwide survey of drugs-resistant tuberculosis in the United States. JAMA 1994; 271:665-71
13. Cohn DL, Catlin BJ, Peterson KL, et al. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990; 112:407-15
14. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis: second report: the results up to 24 months. Tubercle 1982: 63:89-98
15. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990; 112:397-406
16. Weis SE, Slocuin PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179-84
17. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333:229-33
18. Kujiwara PI, Crawford PT, Woodley CL, et al. Drug-resistant tuberculosis in New York City. 1991-1994 [abstract]. Tubercle Lung Dis 1995; 76:897
19. Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug-resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993; 42:1-8
20. Annas GJ. Control of tuberculosis - the law and the public's health. N Engl J Med 1993; 328:585-88
21. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993; 270:65-68
22. Centers for Disease Control. Outbreak of multidrug-resistant tuberculosis - Texas, California. and Pennsylvania. MMWR 1990; 39:369-72
23. Swai OB, Aluoch JA, Githui WA. et al. Controlled clinical trial of a regimen of two durations for the treatment of isoniazid resistant pulmonary tuberculosis. Tubercle 1988; 69:5-14
24. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986; 133:423-30
25. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-32
26. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:1359-74
27. East and Central African/British Medical Research Council Fifth Collaborative Study. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tubercle 1986; 67:5-15
28. Haddix AC, Teutsch SM, Shaffer PA, et al. A guide to prevention effectiveness: decision and economic analysis. Atlanta: Centers for Disease Control, 1994
29. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987
30. Nardell E, McInnis B, Thomas B, et al. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986; 315:1570-75
31. Statistical abstract of the US Table No. XXX: consumer price indexes. Washington. DC: Bureau of Labor Statistics. 1994
32. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329:784-91
33. Iseman MD, Cohn DL, Sbarbaro JA. Directly observed treatment of tuberculosis: we can't afford not to try it. N Engl J Med 1993; 328:576-78
34. Fox W, Nunn AJ. The cost of antituberculosis drug regimens. Am Rev Respir Dis 1979; 120:503-09
35. Bloch AB, Brown ED, Hayden CH, et al. Completion of tuberculosis therapy in the US [abstract]. Am J Respir Crit Care Med 1995; 151:A555
36. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155:1595-1600
37. Weidhass S, Nardell E, Ford J. The economic consequences of a single. uncontrolled case of drug resistant tuberculosis among the homeless [abstract]. Am Rev Respir Dis 1988; 137:A23
38. Adler JJ, Smirnoff M. Selcker B. Evaluation of hospital stay for TB patients referred for directly observed therapy [abstract]. Am J Respir Crit Care Med 1995; 151:A514
39. Rosenblum LS, Castro KG, Dooley S. et al. Effect of HIV infection and tuberculosis on hospitalizations and cost of care for young adults in the United States. 1985 to 1990. Ann Intern Med 1994; 121:786-92
40. Alwood K, Keruly J, Moore-Rice K, et al. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994; 8:1103-08